These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23399479)

  • 1. Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5).
    Licht RW;
    J Affect Disord; 2013 Jun; 148(2-3):286-90. PubMed ID: 23399479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse Prevention in Major Depressive Disorder After Successful Acute Electroconvulsive Treatment: a 6-month Double-blind Comparison of Three Fixed Dosages of Escitalopram and a Fixed Dose of Nortriptyline - Lessons from a Failed Randomised Trial of the Danish University Antidepressant Group (DUAG-7).
    Martiny K; Larsen ER; Licht RW; Nielsen CT; Damkier P; Refsgaard E; Lunde M; Straasø B; Christensen EM; Lolk A; Holmskov J; Sørensen CH; Brødsgaard I; Eftekhari SZ; Bendsen BB; Klysner R; Terp IM; Larsen JK; Vestergaard P; Buchholtz PE; Gram LF; Bech P;
    Pharmacopsychiatry; 2015 Nov; 48(7):274-8. PubMed ID: 26529118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy in long-term treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression.
    Januel D; Poirier MF; D'alche-Biree F; Dib M; Olié JP
    J Affect Disord; 2003 Sep; 76(1-3):191-200. PubMed ID: 12943949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.
    Bauer M; Bschor T; Kunz D; Berghöfer A; Ströhle A; Müller-Oerlinghausen B
    Am J Psychiatry; 2000 Sep; 157(9):1429-35. PubMed ID: 10964859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate.
    Franchini L; Zanardi R; Gasperini M; Smeraldi E
    J Clin Psychiatry; 1999 Dec; 60(12):861-5. PubMed ID: 10665634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine.
    Bech P; Stage KB; Larsen JK; Vestergaard P; Gram LF;
    J Affect Disord; 2012 Nov; 140(3):253-9. PubMed ID: 22381949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial.
    Duffy L; Bacon F; Clarke CS; Donkor Y; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Lewis G; Mangin D; Marston L; Moore M; Nazareth I; Wiles N; Lewis G
    Trials; 2019 Jun; 20(1):319. PubMed ID: 31159856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R
    J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group.
    Psychopharmacology (Berl); 1986; 90(1):131-8. PubMed ID: 2876451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group.
    Vestergaard P; Gram LF; Kragh-Sørensen P; Bech P; Reisby N; Bolwig TG
    Psychopharmacol Ser; 1993; 10():190-8. PubMed ID: 8361976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
    Amsterdam JD; Brunswick DJ; Gibertini M
    J Psychiatr Res; 2004; 38(3):259-65. PubMed ID: 15003431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
    Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
    J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study.
    Altamura AC; Dell'Osso B; Buoli M; Zanoni S; Mundo E
    J Clin Psychopharmacol; 2008 Aug; 28(4):406-10. PubMed ID: 18626267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
    J Affect Disord; 1990 Apr; 18(4):289-99. PubMed ID: 2140382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening and treating depressed patients. A comparison of two controlled citalopram trials across treatment settings: hospitalized patients vs. patients treated by their family doctors. Danish University Antidepressant Group.
    Fuglum E; Rosenberg C; Damsbo N; Stage K; Lauritzen L; Bech P
    Acta Psychiatr Scand; 1996 Jul; 94(1):18-25. PubMed ID: 8841672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.